BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Fresh Biopharmas Join the Race to Cutting-Edge Treatments and Testing

  Several companies launched with Series A financing rounds today. Read on for details.

  April 15, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  GSK Halts Two Mid-Stage Studies of ICOS Agonist Feladilimab

  GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.

  April 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  BioAge Makes A Big Bet on Amgen Drug To Target Muscle Aging

  BGE-105 (formerly AMG 986) mimics the production of apelin, a peptide that has been found in animal studies to improve muscle regeneration and decrease mouse frailty.

  April 15, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Policy

  COVID-19 Infection After Vaccine is Rare But Possible, CDC Says

  The U.S. CDC said up to 5,800 people who have been fully vaccinated against coronavirus disease 2019 (COVID-19) have been infected by the novel coronavirus following vaccination.

  April 15, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Genetown

  Research Roundup: UK Variant Not as Lethal as Originally Reported and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  April 15, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Deals

  Thermo Fisher Drops $17.4 Billion to Buy a Popular CRO

  The medical device maker has been dropping money like rain this spring, spending close to $19 billion in acquisitions over the past four months.

  April 15, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Inovio’s DNA Vaccine Generates Robust Responses Against COVID-19 Variants in Study

  Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.

  April 15, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Psychedelic “Magic Mushroom” Compound Shows Promise for Depressive Disorder in Small Study

  A small Phase II study published Wednesday in the New England Journal of Medicine suggests psilocybin, a psychedelic compound found in “magic mushrooms,” may be an effective treatment for moderate-to-severe major depressive disorder.

  April 15, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Pharm Country

  Merck Ditches $425 Million COVID-19 Drug, Refocusing on Another Candidate

  This marks another setback for Merck in the battle against COVID-19 after it shuttered its pandemic vaccine program in January following poor responses in Phase I studies.

  April 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  FDA Needs More Data to Decide on J&J Vaccine Clotting Problem

  The U.S. FDA’s Advisory Committee on Immunization Practices (ACIP) met yesterday to make a recommendation on the current pause of the Johnson & Johnson COVID-19 vaccine.

  April 15, 2021

   · 

  5 min read

   · 

  Mark Terry